Floatz logo

Semaglutide

Mild Autonomous Cortisol Secretion (MACS)

University of Texas Southwestern Medical Centerprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Mild Autonomous Cortisol Secretion (MACS) cohort.

Asset / SponsorPhaseRating
Osilodrostat
Johns Hopkins University
Phase 4BBB
Anakinra
University Hospital, Basel, Switzerland
Phase 3BB
Metyrapone
Mayo Clinic
Phase 2CCC
DARATUMUMAB
M.D. Anderson Cancer Center
Phase 1CC
Edicotinib
M.D. Anderson Cancer Center
Phase 1C
Solu-Cortef
University of Minnesota
Phase 1NR

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →